JP2016539925A - Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 - Google Patents

Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 Download PDF

Info

Publication number
JP2016539925A
JP2016539925A JP2016525584A JP2016525584A JP2016539925A JP 2016539925 A JP2016539925 A JP 2016539925A JP 2016525584 A JP2016525584 A JP 2016525584A JP 2016525584 A JP2016525584 A JP 2016525584A JP 2016539925 A JP2016539925 A JP 2016539925A
Authority
JP
Japan
Prior art keywords
tlr4
seq
antibody
citrullinated
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016525584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539925A5 (enExample
Inventor
ミン， クリスティーナ デ
ミン， クリスティーナ デ
リミン シャン，
リミン シャン，
エマニュエル モネ，
エマニュエル モネ，
グレッグ エルソン，
グレッグ エルソン，
エリック ハッテラー，
エリック ハッテラー，
Original Assignee
ノビミューン エスアー
ノビミューン エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノビミューン エスアー, ノビミューン エスアー filed Critical ノビミューン エスアー
Publication of JP2016539925A publication Critical patent/JP2016539925A/ja
Publication of JP2016539925A5 publication Critical patent/JP2016539925A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/18—Post-translational modifications [PTMs] in chemical analysis of biological material citrullination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
JP2016525584A 2013-10-22 2014-10-22 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 Pending JP2016539925A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894042P 2013-10-22 2013-10-22
US61/894,042 2013-10-22
PCT/EP2014/072606 WO2015059168A1 (en) 2013-10-22 2014-10-22 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018246722A Division JP2019048895A (ja) 2013-10-22 2018-12-28 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Publications (2)

Publication Number Publication Date
JP2016539925A true JP2016539925A (ja) 2016-12-22
JP2016539925A5 JP2016539925A5 (enExample) 2017-11-30

Family

ID=51866128

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016525584A Pending JP2016539925A (ja) 2013-10-22 2014-10-22 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
JP2018246722A Withdrawn JP2019048895A (ja) 2013-10-22 2018-12-28 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
JP2020177986A Pending JP2021006592A (ja) 2013-10-22 2020-10-23 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018246722A Withdrawn JP2019048895A (ja) 2013-10-22 2018-12-28 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
JP2020177986A Pending JP2021006592A (ja) 2013-10-22 2020-10-23 Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物

Country Status (7)

Country Link
US (2) US9688769B2 (enExample)
EP (1) EP3060250A1 (enExample)
JP (3) JP2016539925A (enExample)
CN (1) CN105899231A (enExample)
AU (2) AU2014338991B2 (enExample)
CA (1) CA2928317A1 (enExample)
WO (1) WO2015059168A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523096A (ja) * 2020-04-20 2023-06-01 エデサ バイオテック リサーチ インコーポレイテッド 急性呼吸促迫症候群を治療するための組成物および方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
EP3060250A1 (en) 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
WO2017021552A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
WO2018065300A1 (en) * 2016-10-04 2018-04-12 F. Hoffmann-La Roche Ag System and method for identification of a synthetic classifier
EP3580571B1 (en) 2017-02-07 2023-06-07 Lyfstone B.V. Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening
WO2020225549A1 (en) * 2019-05-06 2020-11-12 The Francis Crick Institute Limited Method for preventing inflammation
JP7807372B2 (ja) * 2019-12-20 2026-01-27 ハドソン インスティチュート オブ メディカル リサーチ Ｃｘｃｌ１０結合タンパク質及びその使用
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065015A2 (en) * 2003-12-10 2005-07-21 Novimmune Sa Neutralizing antibodies and methods of use thereof
US20080050366A1 (en) * 2003-12-10 2008-02-28 Greg Elson Neutralizing antibodies and methods of use thereof
JP2008523048A (ja) * 2004-12-10 2008-07-03 ノビミューン エスアー ｔｏｌｌ様レセプターを標的とする併用療法およびその使用
WO2012096917A1 (en) * 2011-01-10 2012-07-19 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
AU2005272598B2 (en) 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
KR101379693B1 (ko) 2005-08-25 2014-04-10 크리어빌리스 쎄라퓨틱스 에스.피.에이. Ｋ-252ａ 및 그의 유도체의 중합체 컨쥬게이트
CN101248105B (zh) * 2005-08-25 2012-10-10 克雷毕里斯治疗股份公司 K-252a及其衍生物的聚合物缀合物
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
US7712333B2 (en) 2006-03-29 2010-05-11 Asahi Glass Company, Limited Method for smoothing a surface of a glass substrate for a reflective mask blank used in EUV lithography
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
CN101589491B (zh) 2007-07-24 2011-07-27 松下电器产业株式会社 镍氢电池用负极材料及其处理方法以及镍氢电池
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
US9140701B2 (en) * 2009-08-18 2015-09-22 The Board Of Trustees Of The Leland Stanford Junior University Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
WO2015010791A2 (en) 2013-07-24 2015-01-29 Klareskog, Lars Novel antibodies for the diagnosis and treatment of rheumatoid arthritis
EP3060250A1 (en) 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065015A2 (en) * 2003-12-10 2005-07-21 Novimmune Sa Neutralizing antibodies and methods of use thereof
US20080050366A1 (en) * 2003-12-10 2008-02-28 Greg Elson Neutralizing antibodies and methods of use thereof
JP2008523048A (ja) * 2004-12-10 2008-07-03 ノビミューン エスアー ｔｏｌｌ様レセプターを標的とする併用療法およびその使用
WO2012096917A1 (en) * 2011-01-10 2012-07-19 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS RESEARCH & THERAPY, vol. 14, JPN6018025582, 2012, pages 260, ISSN: 0004010037 *
ARTHRITIS RESEARCH & THERAPY, vol. 8, JPN6018025585, 2006, pages 69, ISSN: 0004010038 *
ARTHRITIS&RHEUMATISM, vol. 56, no. 9, JPN6018025574, 2007, pages 2957 - 2967, ISSN: 0004010033 *
ARTHRITIS&RHEUMATISM, vol. 63, no. 1, JPN6018025578, 2011, pages 53 - 62, ISSN: 0004010035 *
RHEUMATOLOGY, vol. 52, JPN6018025580, April 2013 (2013-04-01), pages 1739 - 1747, ISSN: 0004010036 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 118, JPN6018025576, 2008, pages 205 - 216, ISSN: 0004010034 *
薬学用語解説 関節リウマチ, JPN6018025570, 2009, pages 30 - 6, ISSN: 0004010031 *
関節リウマチ（ＲＡ）に対するトシリズマブ使用ガイドライン, JPN6018025571, June 2013 (2013-06-01), pages 30 - 6, ISSN: 0004010032 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523096A (ja) * 2020-04-20 2023-06-01 エデサ バイオテック リサーチ インコーポレイテッド 急性呼吸促迫症候群を治療するための組成物および方法

Also Published As

Publication number Publication date
AU2020230333A1 (en) 2020-10-01
CN105899231A (zh) 2016-08-24
CA2928317A1 (en) 2015-04-30
EP3060250A1 (en) 2016-08-31
AU2014338991B2 (en) 2020-06-11
AU2014338991A1 (en) 2016-05-26
US20170298140A1 (en) 2017-10-19
US9688769B2 (en) 2017-06-27
US10556960B2 (en) 2020-02-11
JP2019048895A (ja) 2019-03-28
JP2021006592A (ja) 2021-01-21
WO2015059168A1 (en) 2015-04-30
US20150110811A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
US10556960B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
US11485787B2 (en) Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
JP6105146B2 (ja) Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体
NZ796440A (en) Anti-TGF-beta antibodies and their use
HK1219512A1 (zh) 用於诊断和治疗炎性肠病的方法
JP2014519522A (ja) 侵食細胞の選択的排除
KR20190038919A (ko) 항-nkg2d 항체로 크론병을 치료하는 방법
WO2017007405A1 (en) Methods and compounds for the alleviation and/or prevention of bone loss
CN106573976A (zh) 抗cd84抗体、包含所述抗体的组合物及其用途
SG11202107319PA (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
DK2984108T3 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
US20170038381A1 (en) Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
US20250011423A1 (en) Methods to reverse treml1-induced immune suppression
EP4138917A1 (en) Methods and treatment involving antibodies to il-18
EP4093766A1 (en) Anti-il- 1 beta antibodies
WO2026020127A2 (en) Methods of assessing citrullination and activity of pad2 modulators
Notarnicola Studies on pathogenesis, clinical features and comorbidities of idiopathic inflammatory myopathies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402